Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Chong Kun Dang Pharmaceutical.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Chong Kun Dang Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01560325
First received: March 19, 2012
Last updated: July 24, 2012
Last verified: July 2012
  Purpose

A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection on twice-weekly schedule in patients with advanced solid cancers failed to standard therapy. The usefulness of the this regimen is evaluated by response rate, progression free survival and vascular disruption effect by Dynamic Contrast-Enhanced MRI (DCE-MRI) or DWI.


Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
Drug: CKD-516 inj.
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 Inj. Administered on A Twice-Weekly Schedule in Patients With Advanced Solid Cancers Failed to Standard Therapy

Resource links provided by NLM:


Further study details as provided by Chong Kun Dang Pharmaceutical:

Primary Outcome Measures:
  • MTD, Maximum Tolerated Dose [ Time Frame: up to 21days (1st cycle) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • PK parameter of CKD-516 [ Time Frame: 0, 24hrs post dose (1st cycle:Day 1), 0, 0.5, 4, 8, 24hours post-dose(1st cylcle: Day 11) ] [ Designated as safety issue: No ]
  • DLT, Dose-limiting Toxicity [ Time Frame: up to 21days(1st cycle) ] [ Designated as safety issue: Yes ]
  • ORR%, Objective response rate [ Time Frame: approximately 42 days (every 2 cycles) ] [ Designated as safety issue: Yes ]
  • Vascular disruption effect [ Time Frame: 4hr, 24hr post-dose(1st cycle: Day 1) ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: June 2012
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CKD-516 inj.
CKD-516 Inj, 3.3~12mg/m2/day, D1, 4, 8, 11 every 3 weeks
Drug: CKD-516 inj.
CKD-516; 3.3, 5, 7, 9 ~ mg/m2/day Day 1, 4, 8, 11 every 3 weeks
Other Name: CKD-516

Detailed Description:

This is an open label, dose escalation study. Patients receive CKD-516 IV over 30 minutes on day 1, 4, 8, 11 every 3 weeks in the absence of unacceptable toxicity or disease progression. Cohorts of 3~6 patients receive escalating doses of CKD-516 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.

  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 20~75 years
  • Histologically or cytologically confirmed solid tumors that have failed to standard therapy or for which no life prolonging treatment exists
  • ECOG PS 0-2
  • Life expectancy 12 weeks
  • Hematopoietic: ANC ≥ 1,500/mm3, Platelet ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL, Prothrombin time, Activated partial thromboplastin time: normal range
  • Hepatic: total bilirubin ≤ 1.5×ULN(except Gilbert's syndrome patients), AST, ALT ≤ 3.0×ULN(AST, ALT ≤ 5.0×ULN in case of liver metastases)
  • serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min
  • PT, APTT: normal range
  • Signed a written informed consent

Exclusion Criteria:

  • Brain or Leptomeningeal metastases
  • History of Ischemic heart disease(e.g., myocardial infarction, unstable angina pectoris) or Clinically significant heart disease such as NYHA Class III and IV Congestive atrial arrhythmias, within 6 months prior to first dose of study drug
  • Stable angina pectoris shown symptoms within 6 months prior to first dose of study durg, or Clinically significant abnormality on EKG or echocardiogram(e.g., LVEF < 50% or clinically significant heart wall abnormality or heart muscle damage)
  • Cerebrovascular disease such as stroke
  • Grade 2 or greater motor or sensory peripheral neuropathy
  • Uncontrolled hypertension(greater than 150 mmHg systolic or 100 mmHg diastolic regardless of medication)
  • acute infection or blooding tendencies that would preclude study compliance
  • Serious vascular disease such as Aortic aneurysm
  • Other psychiatric disorders or other conditions that would preclude study compliance
  • Receiving anticoagulation with warfarin, heparin, etc.
  • Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 3 weeks prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks for radiation therapy)
  • Other concurrent antitumor therapy
  • Patients with serious hypersensitivity history or allergy to CKD-516
  • Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective contraception
  • Participation in a clinical trial within 4 weeks of first dose of study drug
  • Patients judged to be inappropriate for this study by the investigator with other reasons
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01560325

Contacts
Contact: Yung-Jue Bang 82-2-2072-2390 bangyj@snu.ac.kr

Locations
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of
Contact: Yung-Jue Bang         
Sponsors and Collaborators
Chong Kun Dang Pharmaceutical
Investigators
Principal Investigator: Yung-Jue Bang Seoul National University Hospital
  More Information

No publications provided

Responsible Party: Chong Kun Dang Pharmaceutical
ClinicalTrials.gov Identifier: NCT01560325     History of Changes
Other Study ID Numbers: 127ASC12A
Study First Received: March 19, 2012
Last Updated: July 24, 2012
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

ClinicalTrials.gov processed this record on September 18, 2014